Defence Therapeutics Income Statement

Financials in millions CAD. Fiscal year is July - June.

Millions CAD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2019
Selling, General & Admin	2.7	2.96	2.6	3.14	1.06	0.06	Upgrade
Research & Development	1.06	3.86	3.58	3.76	1.16	0.43	Upgrade
Operating Expenses	4.52	12.75	6.49	7.27	2.83	0.67	Upgrade
Operating Income	-4.52	-12.75	-6.49	-7.27	-2.83	-0.67	Upgrade
Interest Expense	-0.45	-0.4	-0.26	-	-	-	Upgrade
Interest & Investment Income	0	0.02	0.01	-	-	-	Upgrade
Currency Exchange Gain (Loss)	-0.06	0	-0.07	-0.02	-	-	Upgrade
Other Non Operating Income (Expenses)	1.16	-0.08	-0.05	-0.05	-0.03	-	Upgrade
Pretax Income	-3.71	-13.19	-6.87	-7.34	-2.86	-0.67	Upgrade
Income Tax Expense	-	-	-0.11	-	-	-	Upgrade
Net Income	-3.71	-13.19	-6.76	-7.34	-2.86	-0.67	Upgrade
Net Income to Common	-3.71	-13.19	-6.76	-7.34	-2.86	-0.67	Upgrade
Shares Outstanding (Basic)	48	45	40	36	27	1	Upgrade
Shares Outstanding (Diluted)	48	45	40	36	27	1	Upgrade
Shares Change (YoY)	7.87%	12.54%	9.93%	35.65%	2719.76%	-	Upgrade
EPS (Basic)	-0.08	-0.30	-0.17	-0.20	-0.11	-0.71	Upgrade
EPS (Diluted)	-0.08	-0.30	-0.17	-0.20	-0.11	-0.71	Upgrade
Free Cash Flow	-3.09	-4.49	-7.72	-6.04	-2.29	-0.13	Upgrade
Free Cash Flow Per Share	-0.07	-0.10	-0.20	-0.17	-0.09	-0.14	Upgrade
EBITDA	-4.45	-12.68	-6.48	-	-	-	Upgrade
D&A For EBITDA	0.07	0.07	0.01	-	-	-	Upgrade
EBIT	-4.52	-12.75	-6.49	-7.27	-2.83	-0.67	Upgrade
Advertising Expenses	-	1.71	1.96	2.52	-	-	Upgrade

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.